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ABSTRACT
Ikaros and Foxp1 are transcription factors that play key roles in normal 
lymphopoiesis and lymphoid malignancies. We describe a novel physical and functional 
interaction between the proteins, which requires the central zinc finger domain of 
Ikaros. The Ikaros-Foxp1 interaction is abolished by deletion of this region, which 
corresponds to the IK6 isoform that is commonly associated with high-risk acute 
lymphoblastic leukemia (ALL). We also identify the Gpr132 gene, which encodes 
the orphan G protein-coupled receptor G2A, as a novel target for Foxp1. Increased 
expression of Foxp1 enhanced Gpr132 transcription and caused cell cycle changes, 
including G2 arrest. Co-expression of wild-type Ikaros, but not IK6, displaced Foxp1 
binding from the Gpr132 gene, reversed the increase in Gpr132 expression and 
inhibited G2 arrest. Analysis of primary ALL samples revealed a significant increase 
in GPR132 expression in IKZF1-deleted BCR-ABL negative patients, suggesting that 
levels of wild-type Ikaros may influence the regulation of G2A in B-ALL. Our results 
reveal a novel effect of Ikaros haploinsufficiency on Foxp1 functioning, and identify 
G2A as a potential modulator of the cell cycle in Ikaros-deleted B-ALL.
INTRODUCTION
Progression through B cell differentiation is tightly 
regulated by a specific transcription factor program in 
which members of the Ikaros and forkhead families have 
key roles. Ikaros is a Kruppel-like factor [1, 2] whose 
expression has been shown to be absolutely required for B 
cell development [3]. Mice that are null for Ikaros exhibit 
a block in B cell differentiation at a very early stage of the 
differentiation process, before the cells reach the pro-B 
cell stage [3], whereas mice that have a conditional Ikaros 
deletion at the pro-B cell stage show a block in pro-B to 
pre-B cell differentiation [4, 5]. Ikaros plays essential roles 
in regulating cell cycle exit during the transition from the 
large cycling pre-B to the small resting pre-B cell stage 
by downregulating expression of the pre-B cell receptor, 
which stimulates pre-B cell proliferation [6–8]. Genome-
wide analysis of Ikaros binding to gene promoters has also 
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revealed occupancy of a wide-range of promoters of genes 
that are involved in regulation of B cell differentiation [9].
Mutations and deletions in the IKZF1 gene, 
which encodes Ikaros, are particularly associated 
with Philadelphia positive (Ph+, also known as BCR-
ABL positive) B-ALL and are present in 70-80% of 
these patients. In the majority of these cases, Ikaros 
haploinsufficiency is caused by complete or partial gene 
deletion, which frequently results in expression of a 
dominant negative IK6 isoform that lacks the central zinc 
finger DNA-binding domain [10–12]. Several studies 
have shown IKZF1 deletions to be associated with poor 
outcome in both Ph+ and Ph- B-ALL, suggesting that 
Ikaros haploinsufficiency is likely to contribute directly to 
poor treatment response in these patients [13–15].
Foxp1 is a member of the forkhead family of 
transcription factors, which has been shown to be required 
for B cell development [16, 17]. Foxp1 null mice have a 
block on B cell differentiation at the pro-B cell stage and 
Foxp1 has been implicated as an activator of the Erag 
enhancer, which controls expression of the Rag genes [16]. 
Foxp1 has also been implicated in pre-B cell differentiation 
and control of mature B cell numbers. Knockdown of the 
microRNA miR-34a increases expression of Foxp1 in pre-B 
cells and results in increased numbers of mature B cells, 
while leaving pro- and pre-B cell numbers unaffected [18]. 
This result has led to the suggestion that the level of Foxp1 
influences the rate of differentiation of pre-B cells into 
immature and mature B cells [18].
The Gpr132 gene encodes the G2A protein, which 
was originally identified as an orphan G protein-coupled 
receptor (GPCR) that is induced by DNA damage and 
stress and blocks cells in G2/M [19]. Mice that are null for 
the Gpr132 gene exhibit a severe late-onset autoimmune 
syndrome, which is characterised by abnormal expansion 
of both T and B lymphocytes [20]. The G2A protein has 
been shown to act as a tumour suppressor in mouse pre-B 
cells where it antagonises the effect of BCR-ABL [21]. 
However, it also has oncogenic properties when expressed 
in NIH3T3 fibroblasts [22]. These results indicate that 
Gpr132 expression has different effects on the cell cycle 
and proliferation depending on context and suggest that 
varying levels of expression of the gene could influence 
the behaviour of cancers in complex ways.
In this study, we identify a novel interaction between 
Ikaros and Foxp1 in pre-B cells and B-ALL cells, which is 
abolished by the IK6 deletion. We also show that Gpr132 
is a target for activation by Foxp1 through direct binding to 
the gene. Overexpression of Foxp1 in pre-B cells results in 
increased Gpr132 transcription and significant effects on 
the cell cycle, including G2 arrest. Co-expression of wild-
type Ikaros, but not the IK6 deletion mutant, antagonises 
the enhancing effects of Foxp1 on Gpr132 transcription 
and blocks the G2 arrest phenotype. We also show that 
GPR132 levels are significantly increased in BCR-ABL-
negative B-ALL patients that have the IK6 deletion. Our 
results provide evidence of an interplay between two key 
regulators of the cell cycle in B-ALL and suggest that 
GPR132 expression could be a parameter that influences 
cell cycle behaviour and outcome in these patients.
RESULTS
Ikaros and Foxp1 interact in vitro and in vivo
The possibility that Ikaros and Foxp1 interact directly 
or as part of a multi-protein complex in pre-B cells was tested 
by co-immunoprecipitation (co-IP) of protein lysates obtained 
from wild-type murine fetal liver pre-B cells with anti-Ikaros 
and anti-Foxp1 antibodies. IP of a pre-B cell lysate with anti-
Ikaros antibody showed a significant pulldown of Foxp1 
(Figure 1A). In order to confirm the interaction further, 
constructs that encoded HA-tagged Ikaros and FLAG-
tagged Foxp1 were co-transfected into 293T cells. Reciprocal 
pulldowns with anti-FLAG and anti-Ikaros demonstrated that 
the tagged proteins interact strongly in 293T cells (Figure 
1B). Treatment of the extracts with DNase I had no effect on 
the pulldowns (Supplementary Figure S1A) and a non-DNA-
binding Ikaros 159A mutant [23] was also shown to interact 
with Foxp1 in pulldown assays in 293T cells (Supplementary 
Figure S1B). These results demonstrate that the interaction 
was not dependent on the two factors binding simultaneously 
to the same DNA region.
The Ikaros and Foxp1 proteins contain multiple 
domains that are involved in mediating their DNA 
binding and protein-protein interaction functions 
(Figure 2A and 2B). To identify regions that are involved 
in the interaction between the two proteins, a series of 
deletions was generated in both proteins and the effect on 
the Ikaros-Foxp1 interaction was tested using an in vitro 
GST pulldown assay and by co-expression of the proteins 
in 293T cells (Figure 2C and 2D). In vitro pulldown 
using bacterially expressed GST-Foxp1 fusion protein 
and 35S-labelled Ikaros generated by in vitro translation 
demonstrated that Ikaros and Foxp1 interact directly 
(Figure 2C, lanes 1-3 WT Ikaros). The Ikaros protein 
contains a central zinc finger domain (Figure 2A) that 
comprises four zinc fingers and is responsible for DNA 
binding specificity. The C-terminal region of the protein 
contains two zinc fingers and has been shown to mediate 
protein-protein interactions [24]. Deletion of exons 
3-6, which encode the four central zinc fingers, created 
a truncated protein that is equivalent to the human IK6 
mutant (Figure 2A). The IKΔC458 deletion removed the 
two C-terminal zinc fingers that mediate the formation 
of homo- and heterodimers, whereas the IKΔ235-362 
deletion removed a major part of the region between the 
two zinc finger domains. Analysis of the effect of the 
deletions on the efficiency of pulldown by GST-Foxp1 
showed that the IK6 deletion reduced binding to 2% of 
the level observed for the wild-type protein (Figure 2C, 
lanes 4-6). The IKΔ235-262 and IKΔC458 deletions 
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gave reductions of 40% and 50% of wild-type binding 
levels respectively (Figure 2C, lanes 7-12). This suggests 
minor additional contributions from these regions to 
the interaction, which could be due to effects on the 
3-dimensional structure of the protein. Our results indicate 
that the DNA binding region of Ikaros has a major role in 
the interaction with Foxp1 and show that deletion of this 
region is sufficient to abrogate the interaction.
The interaction domains in the Foxp1 protein 
were analysed by co-expressing FLAG-tagged Foxp1 
deletion mutants with wild-type Ikaros in 293T cells 
(Figure 2B and 2D). All of the Foxp1 deletion mutants 
interacted efficiently with Ikaros with the exception of a 
deletion that removed the forkhead domain (Δ477-658), 
which is known to mediate binding to its consensus DNA 
recognition sequence [25]. Overall, the data from the 
deletion analysis demonstrate that the main interaction 
domains are located in the zinc finger DNA binding region 
of Ikaros and the forkhead DNA binding region of Foxp1.
The human Ikaros and FOXP1 proteins interact 
in B-ALL cells and this interaction is abolished 
by the IK6 deletion
The human Ikaros and FOXP1 proteins show greater 
than 90% homology with their counterparts in the mouse, 
suggesting that the human proteins are also likely to 
interact. To test whether this is the case, tagged human 
Ikaros and FOXP1 proteins were initially co-expressed 
in 293T cells. Reciprocal pulldown of both proteins in 
extracts from the transfected cells using antibodies that 
recognise the tags provided a clear demonstration that they 
interact (Figure 3A). When the cells were co-transfected 
with human IK6 and FLAG-tagged FOXP1 expression 
constructs, IP with anti-FLAG antibody showed that the 
IK6 protein does not co-IP with FOXP1 in this system 
(Figure 3A). In vitro pulldown with the GST-FOXP1 
fusion protein showed that pulldown of human IK6 was 
drastically reduced compared with the pulldown observed 
with wild-type human Ikaros (Figure 3B).
To determine whether the interaction between Ikaros 
and FOXP1 occurs in the context of human B-ALL, co-
IP analysis was carried out using nuclear extracts from 
REH and SUP-B15 human B-ALL cell lines. REH 
cells express wild-type Ikaros. The SUP-B15 line has a 
heterozygous IKZF1 deletion and expresses both the IK6 
isoform and wild-type Ikaros (Figure 3C). Co-IP of extract 
from REH cells with anti-FOXP1 resulted in pulldown 
of wild-type Ikaros (Figure 3C, left panel). In contrast, 
the co-IP of SUP-B15 extract with anti-FOXP1 did not 
detect pulldown of the IK6 isoform, although we cannot 
exclude the possibility that there is some interaction that 
is below the detection level of the blot (Figure 3C, right 
panel). Together with the data from the in vitro pulldown 
with GST-FOXP1, these results provide strong evidence 
that that the IK6 deletion disrupts the Ikaros-FOXP1 
interaction in B-ALL cells. Co-IP with the anti-FOXP1 
antibody also gave much less pulldown of wild-type 
Ikaros from SUP-B15 lysates compared to REH cells. 
The apparent reduction in the interaction of FOXP1 with 
Figure 1: Ikaros and Foxp1 proteins interact in vivo. A. Protein extracts from murine fetal liver pre-B-cells were subjected to 
IP with anti-Foxp1 and anti-Ikaros antibodies and with control Ig and immunoblotted with anti-Foxp1. Arrows indicate full-length Foxp1 
(Foxp1A) and IgH. The higher mobility bands are likely to be shorter Foxp1 splicing isoforms that are precipitated by the anti-Ikaros and 
anti-Foxp1 antibodies. B. IPs were carried out on protein lysates from 293T cells following co-transfection with FLAG-tagged Foxp1 and 
HA-tagged Ikaros constructs. Left panel: IP with anti-FLAG (Foxp1); immunoblotting with anti-HA (Ikaros). Right panel: IP with anti-
Ikaros; immunoblotting with anti-FLAG (Foxp1). IP was carried out with anti-Ikaros antibody because the tagged Ikaros was only weakly 
precipitated from extracts by anti-HA, most likely due to epitope occlusion. Input for (A) and (B) = 5% of amount of protein lysate used 
for IPs.
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wild-type Ikaros could be partly due to the reduced levels 
of wild-type Ikaros in the SUP-B15 line (see Figure 3C, 
right panel, input lane), but it could also be caused by 
sequestration of wild-type Ikaros by IK6 [24]. It should 
also be noted that previous studies have shown that uptake 
of IK6 into the nucleus has been shown to be significantly 
reduced compared with wild-type Ikaros [26]. However, 
in cells that express both wild-type and IK6 isoforms, as 
is the case in the SUP-B15 cell line, dimerization between 
wild-type Ikaros and IK6 has been shown to result in 
Figure 2: Identification of the interaction domains in Ikaros and Foxp1. A. Schematic representation of the zinc-finger domains 
of mouse Ikaros. B. Schematic representation of the functional domains of mouse Foxp1. C. Mapping of the Foxp1 interaction domain in 
the Ikaros protein by GST pulldown (see Methods). The upper panel shows pulldowns of S35- labelled Ikaros-deletion proteins with GST 
(lanes 2, 5, 8 and 11) or with GST-Foxp1 (lanes 3, 6, 9 and 12). Ikaros deletions are shown schematically in (A). The middle panel shows 
the coomassie-stained gel confirming the presence of GST and GST-Foxp1. The lower panel shows the results of the quantification of the 
pulldown bands in the upper panel. Values are represented as percentage binding relative to the wild-type value, which was set at 100%. 
The results shown are the mean of 3 experiments. Values for each pulldown were calculated relative to input. The relative pulldown values 
for wild-type Ikaros were then set at 100% for each experiment, and the value for each deletion was calculated as a percentage of the wild-
type value for that experiment. The mean percentage pulldown and SD for each construct was then calculated. D. Interaction domains in 
the Foxp1 protein were mapped by co-transfection of 293T cells with WT Ikaros and Foxp1 deletion mutants that lack specific structural 
domains (depicted in (B)). Heavy arrows indicate the positions of the Foxp1 deletion proteins on the western blots.
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Figure 3: Interaction of human Ikaros and FOXP1 in B-ALL cells and effect of the IK6 deletion. A. A FLAG-tagged 
human FOXP1 construct was co-transfected into 293T cells with wild-type (wt) human Ikaros constructs (lanes 1 - 3 and 7 - 9), or human 
IK6 (lanes 4 - 6 and 10 - 12). Following IP with anti-FLAG or anti-Ikaros, samples were immunoblotted with anti-Ikaros (left panel) or 
anti-FLAG (FOXP1) (right panel). B. GST pulldown assay using a human GST-FOXP1 fusion and 35S labelled wt human Ikaros or the 
human IK6 isoform. C. Anti-Foxp1 IP of Ikaros isoforms in human leukemia cell lines. The REH line (left panel) expresses WT Ikaros. 
The SUP-B15 line (right panel) expresses wt Ikaros and the IK6 deletion isoform. Arrows indicate wt Ikaros, IK6, FLAG-Foxp1 and IgH 
on the gels.
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nuclear localisation of IK6 [24]. These results suggest 
that failure of IK6 to interact with FOXP1 in the nucleus 
in B-ALL cells could be partly due to a direct effect on 
Ikaros-FOXP1 interaction, as well as being a function of 
cytoplasmic localisation of the IK6 isoform. The overall 
effect on the functioning of FOXP1 would be similar to 
the block on direct interaction demonstrated in Figure 3B.
Foxp1 enhances expression of Gpr132
Both Ikaros and Foxp1 have been shown to affect 
the cell cycle. Ikaros mediates exit of pre-B cells from the 
cell cycle [8] and Foxp1 is able to either increase or block 
proliferation depending on the cellular context [27–29]. 
This led us to consider that the interaction between the 
two proteins might influence cell cycle gene regulation. 
To address this question, we used a retroviral vector to 
overexpress Foxp1 in the B3 mouse pre-B cell line. 
Expression of the tagged Foxp1 was confirmed by western 
blotting (Supplementary Figure S2). A commercially 
available QPCR-based expression array (see Methods) 
was used to search for Foxp1 targets among genes that are 
known to be involved in cell cycle regulation. The results 
of the analysis showed that Gpr132 was the most highly 
upregulated gene in the Foxp1-overexpressing cells, 
compared with empty vector-transduced controls (2.8-
fold increase, Supplementary Table S1). Gpr132 mRNA 
levels were further quantified by qRT-PCR analysis, 
which showed a mean 5-fold increase in transcription in 
the Foxp1 overexpressing cells (p<0.001, n = 3 biological 
replicates) (Figure 4A, Foxp1).
Since the interaction of Ikaros with the DNA binding 
domain might be expected to affect the action of Foxp1 
on the Gpr132 gene, we tested whether co-expression of 
Ikaros with Foxp1 affected Gpr132 expression levels. 
Overexpression of Ikaros alone had no effect on Gpr132 
expression (Figure 4A, WT Ikaros), but co-expression of 
Ikaros with Foxp1 abolished the upregulation of Gpr132 
expression that was observed with Foxp1 only (Figure 4A, 
WT Ikaros +Foxp1). In contrast, co-expression with the 
IK6 isoform, which lacks the Foxp1 interaction domain, 
did not affect the Foxp1-mediated increase in Gpr132 
expression (Figure 4A, IK6 +Foxp1).
Binding of Foxp1 to the Gpr132 gene is inhibited 
by wild-type Ikaros but not by IK6
To identify regions within or flanking the Gpr132 
gene that might be Foxp1 targets in B cells, ENCODE 
data for the gene and surrounding sequences obtained 
from adult (8 week-old) murine B-cells (https://www.
encodeproject.org/) were mined for candidate enhancer 
elements. The search identified two regions of DNase 
I hypersensitivity located upstream and downstream 
from the promoter (designated as Regions A and B 
respectively). Analysis of the sequences of the two regions 
identified a Foxp1 consensus binding site at -1kb relative 
to the transcription start site (TSS) and four consensus 
sites at +4kb relative to the TSS (Figure 4B).
B3 pre-B cells were infected with a retroviral 
vector expressing FLAG-tagged Foxp1. Chromatin 
immunoprecipitation (ChIP) analysis with anti-FLAG 
antibody was used to assess binding of Foxp1 to Regions A 
and B. The ChIP analysis showed strong binding of Foxp1 
relative to background in both regions. Co-transduction 
with a vector that expressed wild-type Ikaros reduced 
binding to near-background levels (Figure 4C). Importantly, 
transduction with a vector that expressed the IK6 isoform 
of Ikaros had no effect on binding of Foxp1 to Regions A 
or B. These results demonstrate that Gpr132 expression is 
positively regulated by Foxp1 and that this regulation is 
antagonised by the interaction with Ikaros, but not by Ikaros 
isoforms that lack the DNA binding domain.
The human GPR132 gene and its surrounding 
sequences were also searched for the presence of 
consensus FOXP1 binding sites. Two regions containing 
consensus sites were identified at approximately 3.5 kb 
upstream from the start site and 2 kb downstream in the 
first intron (Supplementary Figure S4A). We performed 
ChIP analysis of REH cells with anti-FOXP1 antibody, 
which showed binding of FOXP1 to both regions 
(Supplementary Figure S4B). These data therefore 
support the hypothesis that FOXP1 is directly involved in 
regulating expression of human GPR132, and suggest the 
existence of a functional homology between regulation of 
the mouse and human genes in pre-B cells.
Ikaros antagonises cell cycle effects of Foxp1 and 
this effect is abolished by the IK6 deletion
The results described above indicate that Foxp1 
enhances expression of the Gpr132 gene, which is known 
to affect cell cycle progression [19, 30] and that Ikaros 
interacts directly with Foxp1 and antagonises its effect 
on Gpr132 expression. To directly test whether cell cycle 
effects of Foxp1 expression are modulated by Ikaros, B3 
cells were transduced with Foxp1- and Ikaros-expressing 
retroviral vectors, either singly or together. Propidium 
iodide staining and FACS analysis were used to measure 
the effect on cell cycle profiles.
The results of 7 biological replicate experiments 
are shown in Figure 5A and 5B. Overexpression of Foxp1 
resulted in cell cycle arrest with a significant proportion 
of cells accumulating in G2/M and variable reduction 
of the number of S-phase cells and exit into G1. Co-
expression of Ikaros and Foxp1 abolished the effect of 
Foxp1 on the cell cycle. In 3 of the 7 experiments, the 
effect of co-transducing IK6 and Foxp1 expression vectors 
was also measured (Figure 5B). In contrast to the effect 
of co-expressing wild-type Ikaros, co-expression of IK6 
and Foxp1 did not prevent the increased G2/M arrest that 
resulted from the expression of Foxp1 alone (Figure 5B).
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Figure 4: Ikaros antagonises the activating effect of Foxp1 on Gpr132 expression. A. qRT-PCR analysis of Gpr132 expression 
in B3 cells expressing ectopic wild-type (wt) Ikaros, IK6 and Foxp1. Gpr132 levels are expressed relative to cells transduced with empty 
vector control, therefore levels > 1 indicate increased expression. Values are the mean ± SEM of 3 biological replicates. Immunoblotting 
analysis showed similar levels of expression of Foxp1 and Ikaros in single and double transductions (Supplementary Figure S2). 
B. Schematic representation of the mouse Gpr132 gene showing the positions of Regions A and B. The sequences of the two regions are 
shown underneath with the Foxp1 consensus binding sequences indicated by boxes. C. ChIP analysis of FLAG-Foxp1 binding to Regions 
A and B of the Gpr132 gene. Results were expressed as % input precipitated in excess of background levels determined by amplification of 
two separate ‘gene-free’ regions of the genome (N1 and N2; see Methods). Values = mean ± SEM. n = 3 biological replicates.
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Figure 5: Cell cycle effects of Foxp1 are antagonised by wild-type Ikaros but not by IK6. A. Percentage of cells at different 
stages of the cell cycle analysed by PI staining and FACS. Data was obtained from 4 experiments where B3 pre-B cells were transduced 
with Ikaros and/or Foxp1 retroviral expression constructs. Individual percentage values (rounded to whole numbers) are shown within the 
histograms. Examples of the FACS profiles used to generate the cell cycle charts are shown in Figure S3. B. Percentage of cells at different 
stages of the cell cycle for 3 additional experiments where the effect of transducing cells with an IK6 expression vector on Foxp1-induced 
cell cycle changes was compared with the effect of expressing wild-type Ikaros.
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IKZF1 deletion is associated with higher 
GPR132 expression in BCR-ABL negative 
B-ALL patients
The results described above suggest that the 
availability of Ikaros protein to interact with nuclear 
Foxp1 directly affects downstream gene regulation 
by Foxp1. This led us to speculate that mutations and 
deletions that reduce the level of WT Ikaros could 
result in aberrant regulation of GPR132 expression in 
human B-ALL. To test this hypothesis directly, RNA 
was extracted from primary samples of human B-ALL at 
diagnosis and analysed for GPR132 expression by qRT-
PCR. The patient cohort included both BCR-ABL positive 
cases that have a high incidence of Ikaros deletions, and 
BCR-ABL negative cases that comprised both Ikaros 
WT and Ikaros-deleted samples (for details of deletions, 
see Supplementary Table S2). The analysis revealed 
a statistically significant (p<0.05) increase of 61% in 
levels of the GPR132 transcript in Ikaros-deleted cases 
within the BCR-ABL negative group of patients, when 
compared with their Ikaros WT counterparts (Figure 6). In 
contrast, for patients in the BCR-ABL positive cohort, no 
significant difference in GPR132 expression was observed 
between samples that did or did not have Ikaros deletions. 
Analysis of FOXP1 expression levels in the same patient 
samples showed no evidence of increased FOXP1 
expression (Supplementary Figure S5A) and no detectable 
correlation between the expression levels of FOXP1 and 
GPR132 (Supplementary Figure S5B), indicating that the 
increased GPR132 expression is not caused by increased 
expression of FOXP1.
DISCUSSION
The results of this study reveal the existence 
of a novel interaction between Ikaros and Foxp1 that 
modulates the activating effect of Foxp1 on expression 
of the G protein-coupled receptor G2A, and potentially 
affects cell cycle progression in B lymphocytes. Our data 
additionally suggest that impairment of this interaction by 
the IK6 isoform alters G2A expression and could affect 
the cell cycle in B-ALL. The interaction does not depend 
on simultaneous binding of the two factors to DNA, but 
our results do not exclude the possibility that the factors 
could interact while binding to the same DNA regions in 
vivo and that this could have phenotypic effects depending 
on the context.
Figure 6. GPR132 levels in primary human B-ALL samples. GPR132 expression was quantified by qRT-PCR. Each point denotes 
the expression of GPR132 in an individual sample relative to a HPRT housekeeping gene control. Ph+ = Philadelphia (BCR-ABL) positive. 
wt = Wild-type. Sample numbers in each group were as follows: Ph+ IKZF1 wt, n= 10; Ph+ IKZF1 Deleted, n = 15; Ph- IKZF1 wt, n = 25; 
Ph- IKZF1 Deleted, n = 15. The indicated p values are the results of statistical comparison of each patient group using a two-tailed unpaired 
t-test. Horizontal bars indicate median levels in each group.
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Ikaros and Foxp1 have important roles in B cell 
development, including the regulation of proliferation and 
cycling of lymphoid progenitors. Ikaros is required for 
progression to the pro- and pre-B cell stages and has a key 
role in cell cycle exit during the transition from the cycling 
large pre-B cell to the non-cycling small pre-B cell where 
light-chain rearrangement takes place. Foxp1 is required 
for efficient production of pre-B cells and is involved in 
regulating expression of the RAG genes. Foxp1 is also 
known to have anti-proliferative effects in several different 
cell types [27–29].
The observation that Ikaros and Foxp1 interact 
opens up an important new dimension to their respective 
functions. The forkhead factors are known to interact with 
a wide range of transcription factors and co-factors as a 
means for diversifying and modulating their functional 
effects during cell differentiation [31]. It is notable that 
the Ikaros family member Eos has been shown to interact 
with the forkhead protein Foxp3 in CD4+ regulatory T 
cells where it plays an important role in Foxp3-mediated 
silencing [32]. In an oncogenic context, physical 
interaction of FOXP3 with the transcription factor RUNX1 
has been shown to regulate the expression of breast cancer 
related genes [33].
We have focused on the effect that the Ikaros-
Foxp1 interaction has on the regulation of the Gpr132 
gene, which we have identified as a novel target for 
upregulation by Foxp1. Binding of Foxp1 to upstream 
and intronic sequences was observed at the mouse and 
human Gpr132 genes. The fact that binding of Foxp1 to 
the mouse Gpr132 gene is antagonised by expression of 
Ikaros suggests that the interaction of Foxp1 with Ikaros 
interferes with its ability to upregulate Gpr132 expression. 
Increased levels of the G2A protein encoded by Gpr132 
have been shown to have complex cell cycle effects that 
include exit into either G2/M or G1, depending on cellular 
context and the action of specific phospholipid modulators 
of G2A function [34]. Interestingly, G2A expression is 
associated with cell cycle exit into G1 in keratinocytes 
[30], which is similar to the effect of Foxp1 on these cells. 
In our experiments, overexpression of Foxp1 resulted 
in cell cycle arrest, mainly in G2/M, and changes in the 
distribution of the different cell cycle stages. This pattern 
was abolished by co-expression with Ikaros, which 
resulted in a shift to a predominantly G1 arrest similar to 
the profile obtained with Ikaros alone. This result supports 
our hypothesis that expression of wild-type Ikaros is 
dominant over the cell cycle effects of Foxp1.
An important finding from our study is the 
observation that the IK6 deletion, which removes the 
Ikaros DNA binding domain and prevents the interaction 
with Foxp1, abolishes the effect of Ikaros expression on 
Foxp1 binding to the mouse Gpr132 gene and on Foxp1-
mediated enhancement of Gpr132 expression. Cells that 
were co-transduced with Foxp1 and the IK6 deletion 
construct had a cell cycle profile similar to cells that 
were transduced with Foxp1 only. This was in contrast 
to the dominant effect of wild-type Ikaros over the cell 
cycle effects of Foxp1 and implies that the IK6 deletion 
is unable to antagonise the effects of Foxp1 on Gpr132 
expression and the cell cycle.
The hypothesis that reduced Ikaros protein levels 
upregulate GPR132 expression was further supported by 
the finding that expression of the gene was significantly 
increased in Ph- B-ALL patients with IKZF1 deletions, 
compared with patients that have wild-type Ikaros. 
Intriguingly, the effects on GPR132 expression were only 
observed in BCR-ABL negative samples, and no increase 
was found in patients that were positive for the BCR-ABL 
translocation. The GPR132 gene product, G2A, has been 
shown to antagonise the oncogenic effects of BCR-ABL 
[21] raising the possibility that downregulation of GPR132 
expression is necessary for BCR-ABL transformation. This 
suggests that the presence of BCR-ABL downregulates 
GPR132 expression, either directly, or through a downstream 
effector, overriding any effects that differences in FOXP1 
binding to the GPR132 gene might have. Conversely, 
absence of the BCR-ABL protein in BCR-ABL-negative 
B-ALL would allow overexpression of GPR132 with the 
additional effects that this overexpression generates.
Current evidence indicates that BCR-ABL-negative 
B-ALL is generated by a complex spectrum of oncogenic 
mechanisms. A subset of BCR-ABL-negative cases have 
a gene expression profile that is similar to that of BCR-
ABL-positive B-ALL and are described as Ph-like B-ALL 
[35]. However, these patients have a range of oncogenic 
lesions [36], including rearrangements involving ABL1, 
ABL2, CRLF2, CSF1R, EPOR, JAK2, NTRK3, PDGFRB, 
PTK2B, TSLP, or TYK2 indicating that heterogeneous 
mechanisms are responsible for the phenotypes that are 
observed. The significant increase in GPR132 expression 
that is associated with haploinsufficiency for IKZF1 in 
these patients adds a potential mechanism for changes to 
the cell cycle that merits further investigation.
GPCRs are known to be overexpressed in a wide 
variety of malignancies, and are considered to be involved 
in cancer initiation, progression and metastasis (Reviewed 
in [37]. GPCRs are established common targets of drugs 
in clinical use, and GPCR antagonists constitute 30-40% 
of marketed drugs in humans [38]. Concerted efforts are 
therefore underway to develop pharmacological GPCR 
antagonists with anti-cancer activity. Our identification of 
increased GPR132 levels in a subset of B-ALL adds to 
a growing body of evidence that GPCRs are aberrantly 
expressed in a spectrum of hematological malignancies. 
Evidence for GPCR dysregulation has been documented 
in acute myeloid leukemia [39], chronic lymphocytic 
leukemia [38, 40] and intestinal T-cell lymphoma [41]. 
Our results, together with the known association of cell 
cycle changes with poor prognosis [42–45] provide a 
rationale for investigation of G2A as a potential target in 
Ikaros-deleted B-ALL.
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MATERIALS AND METHODS
Cell culture
Cells were cultured under the following conditions: 
WT murine pre-B: RPMI + 15% FCS, 2mM L-Glutamine, 
50μM β-mercaptoethanol, 2ng/ml IL-7. 293T: DMEM + 
10% FCS, 2mM L-Glutamine. REH and SUP-B15: RPMI 
+ 20% FCS, 2mM L-Glutamine. B3 pre-B: IMDM+ 10% 
FCS, 2mM L-Glutamine, 50μM β-mercaptoethanol, 2ng/
ml IL-7.
Plasmid constructs
Ikaros and Foxp1 cDNAs were cloned into 
PCDNA3.1 vectors containing either a HA or double 
FLAG epitope tag. For GST-tagged proteins, cDNAs 
were inserted into pGEX-4T (GE lifesciences). Retroviral 
expression constructs were derived from the pMSCV-
IRES-GFP plasmid.
Preparation of nuclear extracts
Protein extracts were prepared as previously 
described [46, 47]. Cells were washed in PBS and initially 
resuspended in a low osmolarity buffer (10mM HEPES 
pH 7.9, 10mM KCl, 0.1mM EDTA and 0.1mM EGTA) 
and allowed to swell on ice for 15 minutes. After addition 
of NP40 (0.6%), the solution was mixed vigorously by 
vortexing, and subjected to centrifugation at 10,000 × g 
at 4°C for 30 seconds. The nuclear pellet was recovered 
and resuspended in a high osmolarity nuclear lysis buffer 
(20mM HEPES pH 7.9, 400mM NaCl, 1mM EDTA 
and 1mM EGTA) and incubated with shaking at 4°C 
for 30 minutes. Nuclear extracts were recovered in the 
supernatant following centrifugation at 10,000 × g at 4°C 
for 5 minutes.
Co-immunoprecipitation
Following treatment with DNase I (Roche), protein 
extracts were incubated with the antibody-coupled G 
Dynabeads (Sigma) for 30 minutes at room temperature. 
Immunocomplexes were eluted by boiling the beads in 1x 
NuPAGE LDS Sample Buffer (Invitrogen) for 10 minutes 
at 70°C. Antibodies are listed in Supplementary Table 
S3. The anti-Ikaros and anti-Foxp1 antibodies used in the 
study recognise the human and mouse proteins.
GST pulldown assay
Ikaros constructs (250 ng) were in vitro transcribed 
and translated with TNT T7 Quick Master Mix (Promega) 
and 35S methionine. For the GST pull-down assay, 15 
μl of GSH–agarose beads and bacterial protein extracts 
containing either GST alone or GST–Foxp1 fusions were 
mixed and incubated at 4°C for 1 hour. Agarose beads 
were washed three times with 0.02 M HEPES–KOH 
pH 7.9, 0.1% NP-40, 0.15 M NaCl, 1 mM DTT and 
protease inhibitors. Immobilized GST proteins were then 
resuspended in 200 μl of the same buffer containing 1 μl 
of the in vitro translated proteins and incubated for 1 h at 
4°C with rotation. The beads were washed three times with 
1 ml of buffer. Proteins were eluted with 20 μl of loading 
buffer and boiled. Bound proteins were separated in a 10% 
SDS–polyacrylamide gel. Dried gels were analysed using 
a Fujifilm FLA-5100 scanner.
Retroviral transduction of B3 cells
293T cells were co-transfected with pMIG retroviral 
vectors and pCL-Eco retrovirus packaging vector. Viral 
supernatant was collected at 48hrs and 72 hrs post-
transfection. B3 cells were transduced with virus by 
spinoculation (700g × 60 minutes) in the presence of 
HEPES (10mM) and Polybrene (4μg/ml). Full details of 
the transduction protocol can be found in Supplementary 
Methods. Transduction efficiency was determined 
by FACS analysis of GFP expression 48 hours after 
transduction. For co-transductions, equal amounts of 
infective units of each virus were used.
Quantitative reverse transcription PCR 
(qRT-PCR)
RNA was extracted using either an RNeasy Mini 
(cell lines) or Micro (primary samples) Kit (Qiagen), and 
retrotranscribed using Superscript III reverse transcriptase 
(Life Technologies). Changes in expression of cell-
cycle-related genes in B3 cells transduced with a Foxp1-
expressing retroviral vector were initially determined 
using the RT2 Profiler™ PCR Array Mouse Cell Cycle 
(Qiagen). Quantification of murine Gpr132 expression 
in further experiments was obtained by normalizing to 
the housekeeping gene Casc3. GPR132 expression in 
human samples was calculated by normalization to HPRT. 
Control and relative expression was calculated by the 
change-in-threshold (−ΔΔCT) method. Primer sequences 
are shown in Supplementary Table S4A (mouse) and S4b 
(human).
Chromatin immunoprecipitation (ChIP)
ChIP was performed on formaldehyde-fixed B3 
cells as described previously [48] using an anti-FLAG 
M2 antibody (Sigma-Aldrich). Primer sequences are 
shown in Supplementary Table S4c (mouse) and S4d 
(human). Binding to Regions A and B was compared with 
two genomic regions (designated N1 and N2), which to 
date have exhibited an absence of transcription factor 
binding in ChIP-sequencing data (N. Kunowska, personal 
communication). The positions of N1 and N2 are: N1: 
Chr17: 86,190,215-86,190,285; N2: Chr4: 55,591,773-
55,591,842 (July 2007 (NCBI37/mm9) Assembly).
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Testing of IKZF1 deletion status
IKZF1 deletion status was determined by analysis of a 
multiplex PCR reaction, as previously described [49]. Briefly, 
genomic DNA was extracted from patient samples using an 
Illustra DNA Extraction Kit BACC2 (GE Healthcare) and 
amplified using Amplitaq Gold® DNA Polymerase (Life 
Technologies) in a mix containing a series of fluorochrome-
labelled primers (sequences available on request). Following 
amplification, PCR products were run on an ABI 3130 
analyzer using a fragment size analysis program. Analyses 
of IKZF1 deletions (indicated by the presence of truncated 
amplification products) were performed using GeneMapper 
software (Applied Biosystems).
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